SiBionics and PharmaSens showcase integrated continuous sensing and automated insulin delivery concepts at EASD 2026
Executive summary: SiBionics and PharmaSens presented their "See More, Act Earlier" initiative at the EASD 2026 congress, linking continuous glucose monitoring with future automated insulin delivery. This signals progress toward integrated diabetes management platforms that could improve patient outcomes and reshape the CGM and insulin pump markets.
Who is involved: SiBionics, PharmaSens, and attendees of the European Association for the Study of Diabetes (EASD) 2026 conference.
Likely next: Further technical disclosures and potential collaboration details are expected to be shared after the conference.
At the European Association for the Study of Diabetes congress in Milan, SiBionics presented its “See More, Act Earlier” initiative alongside PharmaSens, outlining how continuous glucose monitoring could be linked to future insulin delivery systems. The announcement highlights ongoing collaboration between the two firms to advance diabetes technology. No financial terms or timelines were disclosed in the release.
What's next — scenarios
Early-stage feasibility collaboration (base case) (55%)
PharmaSens and SiBionics proceed with a co-development feasibility study, but no device will reach market in the next 12 months; diabetes-device suppliers may see only modest R&D-driven upside.
- Companies announce a joint non-pivotal feasibility study or technical validation program
- EASD poster/abstract details integration architecture without commercial commitments
- No equity investment or licensing fee disclosed within 90 days
Accelerated co-development and regulatory pathway (upside) (25%)
The collaboration matures into a formal development agreement with defined milestones, potentially advancing an automated insulin delivery system toward CE/FDA trials and creating partnership revenue expectations for SiBionics.
- PharmaSens and SiBionics sign a development/option agreement with milestone payments
- An investigational device exemption (IDE) or clinical trial application is filed for the integrated system
- Registry data on glucose sensing algorithm performance is published with real-world outcomes
Stalled or diluted initiative (downside) (20%)
The initiative remains a concept with no contractual follow-through, allowing larger rivals with existing closed-loop systems to consolidate market share and limiting commercial relevance for SiBionics in the near term.
- No joint press releases or scientific disclosures by the end of Q3 2026
- SiBionics focuses resources on standalone sensors rather than integrated delivery
- A major competitor announces a superior integrated sensor-pump partnership with shorter time-to-market
What to watch
- EASD 2026 congress materials and press program for any joint session or technical poster (expected September 2026)
- ClinicalTrials.gov or EUDAMED entries for SiBionics-PharmaSens integrated system, watch August-September 2026
- PharmaSens and SiBionics quarterly/interim management statements in June-August 2026 mentioning collaboration status
- Public statements about capital expenditure or Series funding linked to automated insulin delivery (next 90 days)
- Regulatory clearance announcements for comparable closed-loop systems from competitors during June-August 2026
Timeline
- — SIBIONICS und PharmaSens erkunden auf der EASD 2026 neue Horizonte für die automatisierte Insulinabgabe (PR Newswire)
- — SIBIONICS et PharmaSens explorent de nouvelles perspectives pour l'administration automatisée d'insuline lors du congrès de l'EASD 2026 (PR Newswire)
- — SIBIONICS и PharmaSens исследуют новые горизонты для автоматической доставки инсулина на EASD 2026 (PR Newswire)
- — SIBIONICS a PharmaSens skúmajú na EASD 2026 nové možnosti automatizovaného podávania inzulínu (PR Newswire)
- — SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026 (PR Newswire)
Analysis — what this means
Sectors affected
- Diabetes technology
- Continuous glucose monitoring (CGM)
- Automated insulin delivery (AID) systems
Historical parallels
- Multilingual press releases on Oct 4 2026 previewed the SiBionics‑PharmaSens EASD 2026 presentation (Russian, Slovak, Czech versions)
Key entities
Sources
- SIBIONICS und PharmaSens erkunden auf der EASD 2026 neue Horizonte für die automatisierte Insulinabgabe — PR Newswire
- SIBIONICS et PharmaSens explorent de nouvelles perspectives pour l'administration automatisée d'insuline lors du congrès de l'EASD 2026 — PR Newswire
- SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026 — PR Newswire
- SIBIONICS и PharmaSens исследуют новые горизонты для автоматической доставки инсулина на EASD 2026 — PR Newswire
- SIBIONICS a PharmaSens skúmajú na EASD 2026 nové možnosti automatizovaného podávania inzulínu — PR Newswire
Related cases
- SiBionics and PharmaSens showcase a joint vision for automated insulin delivery at EASD 2026, signaling advancing collaboration in diabetes tech
- SiBionics and PharmaSens present integrated continuous sensing and automated insulin delivery vision at EASD 2026
- Sibionics and PharmaSens announce exploration of integrating continuous glucose sensing with automated insulin delivery at EASD 2026
- Hansoh Pharma’s dual‑biased GLP‑1/GIP agonist olatorepatide achieves 19.3% weight loss at week 48, signalling a new contender in the obesity drug market
- Sinocare launches integrated chronic disease management solutions at EASD 2026, signaling expansion in digital health for diabetes care
- Eli Lilly accelerates cardiometabolic leadership with pivotal new clinical data presentation at EASD 2026